Advertisement
Advertisement

LXRX

LXRX logo

Lexicon Pharmaceuticals, Inc.

1.15
USD
Sponsored
-0.29
-19.86%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

1.17

+0.01
+0.95%

LXRX Earnings Reports

Positive Surprise Ratio

LXRX beat 34 of 40 last estimates.

85%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.20M
/
-$0.07
Implied change from Q3 25 (Revenue/ EPS)
-77.40%
/
+75.00%
Implied change from Q4 24 (Revenue/ EPS)
-87.93%
/
-22.22%

Lexicon Pharmaceuticals, Inc. earnings per share and revenue

On Nov 06, 2025, LXRX reported earnings of -0.04 USD per share (EPS) for Q3 25, beating the estimate of -0.06 USD, resulting in a 40.56% surprise. Revenue reached 14.18 million, compared to an expected 4.74 million, with a 199.06% difference. The market reacted with a +3.62% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 3.20 million USD, implying an increase of 75.00% EPS, and decrease of -77.40% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Lexicon Pharmaceuticals, Inc. reported EPS of -$0.04, beating estimates by 40.56%, and revenue of $14.18M, 199.06% above expectations.
The stock price moved up 3.62%, changed from $1.38 before the earnings release to $1.43 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 7 analysts, Lexicon Pharmaceuticals, Inc. is expected to report EPS of -$0.07 and revenue of $3.20M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement